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Abstract
Study Objectives—To evaluate whether patients with human immunodeficiency virus (HIV)
infection who were receiving protease inhibitor therapy had altered bile acid concentrations
compared with noninfected control subjects, and whether bile acid concentrations could predict
the onset of hepatotoxicity caused by protease inhibitors.
Design—Retrospective sample analysis from a prospectively conducted clinical trial.
Setting—Academic research center.
Patients—Eleven adults with advanced HIV disease who were taking protease inhibitor–based
antiretroviral therapy, one of whom had developed protease inhibitor–induced hepatotoxicity.
Measurements and Main Results—Plasma concentrations of cholic acid (CA),
chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA),
ursodeoxycholic acid (UDCA), and taurocholic acid (TC) were analyzed by using a novel high-
performance liquid chromatography with tandem mass spectrometry detection method.
Comparisons of the relative contribution of each bile acid to the total bile acid pool were made
with previously published values and with bile acid concentrations contained in two pooled
plasma samples from healthy, non–HIV-infected volunteers analyzed in our laboratory. Each
pooled plasma sample used for this analysis contained contributions from three non–HIV-infected
volunteers. The LCA and TC concentrations in HIV-infected patients were 3–4-fold higher than
those previously reported for non–HIV-infected subjects; concentrations of other bile acids were
similar to those of previous reports. The relative contribution of CDCA to the total bile acid pool
was 9% in HIV-infected patients compared with 30–50% in noninfected subjects. Total and
individual bile acid concentrations in the HIV-infected patient who developed hepatotoxicity were
similar to the bile acid concentrations from the other study patients who did not develop
hepatotoxicity.
Conclusion—These data suggest that bile acid concentrations may be altered by HIV infection
and/or protease inhibitor therapy. However, further investigations should be performed to assess
whether antiretroviral-associated hepatotoxicity can be predicted by alterations in individual bile
acid concentrations.
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Liver dysfunction and disease can result in elevations in plasma bile acid concentrations, as
well as perturbations in the relative contribution of each bile acid to the total bile acid pool.
1-8 Total bile acid concentrations and the cholic acid:chenodeoxycholic acid ratio are
elevated in primary sclerosing cholangitis3-6 and cholestasis.5 Hepatotoxicity implicated
from occupational and drug exposure has also been associated with elevations in total bile
acid concentrations.9-13
Recently, we published the results of a clinical investigation conducted in 11 human
immunodeficiency virus (HIV)–infected patients on the pharmacokinetics, safety, and
efficacy of an antiretroviral regimen that included three protease inhibitors: amprenavir,
ritonavir, and saquinavir.14 During that study, drug-induced hepatotoxicity was diagnosed in
one of the 11 patients. In this current study, we used blood samples obtained from that study
to determine whether the average plasma concentrations of individual bile acids of HIV-
infected patients differ compared with a population of non–HIV-infected individuals,
whether protease inhibitor therapy influences bile acid concentrations during a dosing
interval, and whether elevations in total or individual plasma bile acid concentrations might
be an early signal of drug-induced hepatotoxicity.
Methods
Our previously published study was designed to evaluate the safety, efficacy, and
pharmacokinetic changes occurring with triple protease inhibitor–based therapy that
included saquinavir, amprenavir, and ritonavir.14 Real-time pharmacokinetic analyses of
drug exposure and subsequent dosage adjustments of protease inhibitor therapy were
performed in that study. The study was approved by the University of North Carolina at
Chapel Hill institutional review board. Informed consent was obtained from each
participant, and the study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki.
Highly active antiretroviral therapy–experienced HIV-infected patients who were failing
their current regimen were enrolled.14 Patients were prescribed a new regimen of nucleoside
reverse transcriptase inhibitors (based on HIV genotyping results) and were randomly
assigned to receive either a combination protease inhibitor regimen of saquinavir 1000 mg–
ritonavir 100 mg twice/day or amprenavir 600 mg–ritonavir 100 mg twice/day. After taking
this regimen for 7–10 days, a full pharmacokinetic profile was obtained for each patient
(PK1). The third protease inhibitor (either amprenavir or saquinavir) was added to the
regimen, and pharmacokinetic analysis was repeated after 14 days of receiving triple–
protease inhibitor therapy (PK2). Based on the results of PK2, the dosages of each protease
inhibitor were adjusted in order to achieve amprenavir and saquinavir exposures similar to
those seen in patients receiving amprenavir-ritonavir or saquinavir-ritonavir alone.
Additional pharmacokinetic analyses (PK3, PK4) were performed over the next 6 months,
after any necessary dosage adjustments were made to achieve the desired protease inhibitor
concentrations. The PK3 analysis occurred at a median of 15.0 weeks (range 10.6–23 wks)
and PK4 occurred at a median of 23.9 weeks (range 16.6–27.7 wks).
In the current study, we analyzed blood samples obtained from the patients who had
participated in this previously published study14 for quantification of their bile acid
concentrations.
Quantification of Bile Acids
A novel liquid chromatography with tandem mass spectrometry detection method was
developed to simultaneously quantify six predominant bile acids—cholic acid (CA),
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chenodeoxycholic acid CDCA, deoxycholic acid (DCA), lithocholic acid (LCA),
ursodeoxycholic acid (UDCA), and taurocholic acid (TC)—in plasma collected from the
blood samples. All chemicals and solvents were of analytic grade and were used with no
further purification. Methanol was purchased from JT Baker (Phillipsburg, NJ) and
ammonium acetate salt was purchased from Fisher Scientific (Fair Lawn, NJ). Bile acid
standards (CA, CDCA, DCA, LCA, TC, UDCA) and formic acid were purchased from
Sigma Chemical (St. Louis, MO). The N-1 naphthylph-thalamic acid ([NPA] Sigma
Chemical) was used as an internal standard.
Preparation of Plasma Samples
Whole blood was collected in ethylenediamine-tetraacetic acid Vacutainer tubes (Becton
Dickinson, Franklin Lakes, NJ) and centrifuged at 2600 rpm at 4°C within 30 minutes of
collection. Plasma was stored at −70°C until analysis. Plasma samples were subjected to a
solid-phase extraction method. Briefly, extraction cartridges (1.0 ml, 100-mg Bond Elute-
C18; Varian, Harbor City, CA) were conditioned with 1.0 ml of methanol and equilibrated
with ammonium acetate (pH 7.0) 25 mM. Subsequently, 0.4 ml of internal standard (NPA
0.25 μg/ml in ammonium acetate [pH 7.0] 25 mM) and 0.2 ml of plasma were added to the
cartridges and passed through with minimal suction (1–3 mm Hg). The cartridges were
washed with 1.0 ml of ammonium acetate (pH 7.0) 25 mM, and the cartridge bed was
suctioned dry for 1 minute. The bile acids were eluted with 0.8 ml of 100% methanol. The
eluent was evaporated to dryness under a nitrogen stream at 40°C and reconstituted in 100 μl
of a 50:50 mixture of methanol:water. The resultant solutions were mixed by vortex and
centrifuged at 12,000 rpm for 5 minutes. The supernatants were transferred to 200-μl high-
performance liquid chromatography microvials (Agilent Technologies, Santa Clara, CA),
and 3 μl was injected onto the column.
Bile Acid Analysis
Bile acids were analyzed with a triple quadrupole mass spectrometer API 4000 (Applied
Biosystems–Sciex Instruments, Foster City, CA) in the negative-ion mode. Quantitative data
were analyzed in the multiple reaction monitoring mode by using optimal parameters for
each bile acid. Analysis was performed using two acquisition periods to increase the
signal:noise ratio for LCA, the only bile acid within acquisition period 2.
Chromatography was achieved by using a reverse-phase C18 Pinnacle II column (100 × 4.6-
mm internal diameter, 3-μm particle size; Restek, Bellefonte, PA) with a flow rate of 1 ml/
minute. Mobile phase A consisted of 100% NANOpure water and mobile phase B consisted
of 90% methanol–0.05% formic acid. The chromatographic separation of analytes was
performed with gradient elution of mobile phase B (75% from 2–10 min, 95% from 10–17
min, 75% from 17–19 min).
Calibration standard curves ranged from 1.0–1000 ng/ml and were linear throughout this
range except for CDCA, which was linear from 1.0–500 ng/ml. Intra- and interday
coefficients of variation across the range of concentrations were less than 15% for all
analytes. The lower limit of quantification was 10 ng/ml for CA, UDCA, and DCA; 2.5 ng/
ml for LCA; and 1.0 ng/ml for TC and CDCA.
Data Analysis
Comparisons of the relative contribution of each bile acid to the total bile acid pool were
made with previously published values15, 16 and with bile acid concentrations contained in
two pooled plasma samples from healthy, non–HIV-infected volunteers analyzed in our
laboratory. Each pooled plasma sample used for this analysis contained contributions from
three non–HIV-infected volunteers.
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Interpatient variability was calculated among patients for individual bile acids by using PK1,
PK2, and PK3 visits. Intrapatient variability was calculated based on individual mean bile
acid concentrations at PK2 and PK3 for each patient on whom data were available (8 of 11
patients). Area under the concentration-time curve (AUC in μmol•hr/L) during a 12-hour
dosing interval was calculated by using the linear-log trapezoidal rule (WinNonlin version
4.1; Pharsight Corp., Mountain View, CA). Data are presented as mean and SD unless
otherwise indicated.
Statistical Analysis
Statistical analysis was performed by using a mixed model with compound symmetry
covariance structure with the SAS PROC MIXED software, version 9 (SAS Institute Inc.,
Cary, NC). Logarithmic transformation was performed on the bile acid concentration data in
order to meet the assumptions used in the analysis.
Results
In the previously published study, nine male and two female patients with advanced HIV
disease were evaluated.14 Seven patients were African-American and four were Caucasian.
Median age was 44 years (range 26–64 yrs), and mean ± SD HIV-1 RNA and CD4+ T-cell
counts were 5.16 ± 5.33 log copies/ml and 195 ± 128 cells/mm3, respectively, at the time of
enrollment. Patients were highly active antiretroviral therapy experienced, with previous
exposure to a median of 3.5 (range 1–6) protease inhibitors, 1 (0–2) nonnucleoside reverse
transcriptase inhibitors, and 4.5 (2–5) nucleoside reverse transcriptase inhibitors. The
median concentrations at 12 hours for amprenavir, saquinavir, and ritonavir at PK2 were
1.81 μg/ml (range 0.98–4.78 μg/ml), 0.15 μg/ml (0.05–0.48 μg/ml), and 0.15 μg/ml (0.04–
0.63 μg/ml), respectively.
Mean bile acid concentrations during a 12-hour dosing interval at PK1 (dual–protease
inhibitor therapy) and PK2 (triple–protease inhibitor therapy) are shown in Figure 1. There
was a trend toward differences in LCA and TC concentrations in these HIV-infected patients
compared with noninfected subjects.16 Mean LCA concentrations for HIV-infected patients
(15.8–36.3 ng/ml; Figure 1) were greater at all time points than average fasting
concentrations of LCA for non–HIV-infected subjects (1.1–7.5 ng/ml).16 Plasma
concentrations for TC were generally greater in the HIV-infected patients during the 12-hour
dosing interval (105.2–429.7 ng/ml), although some concentrations fell within the published
range for non–HIV-infected subjects (0–128.5 ng/ml).16 The CA, CDCA, UDCA, and DCA
concentrations were similar between HIV-infected patients and noninfected control subjects.
Mean intrapatient variability in AUC for these individual bile acids were 25.9% (range 1.4–
61.9%) for CA, 34.3% (1.1–98.9%) for CDCA, 31.8% (0.2–100.6%) for DCA, 50.3%
(10.6–141.4%) for LCA, 42.6% (8.8–82.4%) for UDCA, and 44.3% (3.9–101.7%) for TC.
Interpatient variability within each of the three PK visits ranged from 53–84% for CA, 49–
92% for CDCA, 79–94% for DCA, 108–157% for LCA, 48-60% for UDCA and 109–215%
for TC. The interpatient variability for CA, DCA, and UDCA was less than what has been
previously reported in noninfected persons (103–115%, 120–125%, and 79%, respectively),
15, 16 whereas the interpatient variability for CDCA and TC was similar to that of historical
reports (62–84% and 110%, respectively).15, 16 Only LCA interpatient variability was
greater in our study patients (108–157%) than what has been previously reported for
noninfected persons (50%).16
The relative contribution of individual bile acids compared with the total bile acid pool is
listed in Table 1. The relative contribution of bile acids was calculated by using the average
AUC values for each bile acid during the three PK visits. The CDCA contribution, a primary
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bile acid which normally constitutes 30–50% of the total plasma bile acid pool,15, 16
represented only 9% of the major bile acids in our HIV-infected patients. The contribution
of TC was 3–4-fold higher in these HIV-infected patients than that of previous reports of
non–HIV-infected subjects.16
Bile acid concentrations were similar with dual (PK1) and triple (PK2) protease inhibitor
therapy (Figures 1 and 2) for all patients. In the one patient who developed hepatotoxicity,
elevations in aspartate (AST) and alanine aminotransferase (ALT) levels occurred between
day 27 (PK2) and day 103 (PK3) of therapy (Figure 3). However, neither individual (Figure
1) nor total (Figure 2) bile acid concentrations increased in this patient, even after AST and
ALT concentrations exceeded 3-fold the upper limit of normal (noted on day 103 of therapy;
Figure 3). Similarly, there was no clear relationship between the CA:CDCA ratio and the
development of AST and ALT elevations in our investigation. This ratio increased slightly
in the patient who developed hepatotoxicity (PK1 0.39, PK2 0.40, PK3 0.48), but was within
the range of ratios for all patients (Figure 4). No association between bile acid
concentrations and such as CD4+ count, concurrent disease states, concomitant drugs, and
cholesterol concentrations was found (data not shown).
Discussion
This investigation was performed to simultaneously measure six plasma bile acid
concentrations in patients taking combination protease inhibitors. Several analyses were
conducted to describe individual bile acid concentrations in these patients. Intra- and
interindividual variability in individual bile acid concentrations were quantified. We also
evaluated whether protease inhibitors altered individual plasma bile acid concentrations,
whether there were differences in plasma bile acid concentrations in HIV-infected patients
relative to noninfected controls, and whether elevations in bile acid concentrations occur
before elevations in serum transaminase levels.
Interpatient variability among our HIV-infected patients was greater for LCA, similar for
CDCA and TC, and smaller for CA, UDCA, and DCA than those in historical non–HIV-
infected controls. To our knowledge, this is the first study to use multiple sampling of
individual bile acid concentrations to calculate intraindividual variability. To determine this
information, we used data from PK2 and PK3. Two confounders may make these results
larger than the nominal value: the protease inhibitor dosage adjustment between PK2 and
PK3, and the sampling of only time points.
In addition, this is the first investigation, to our knowledge, describing individual plasma
bile acid concentrations in HIV-infected patients. Results of this study suggest that plasma
bile acid composition is altered in individuals with advanced HIV infection who are taking
protease inhibitor–based therapy, with the concentrations of LCA and TC being greater than
what has previously been reported for non–HIV-infected individuals.15-17 There are several
possible explanations for these observations. Bile acids are formed from the catalysis of
cholesterol and serve as a major excretory pathway for cholesterol. It has been reported
previously that protease inhibitor therapy (and HIV infection itself) can result in deleterious
elevations in plasma lipid concentrations.18, 19 Therefore, it is possible that an increase in
cholesterol concentrations also could increase bile acid concentrations. Analyses were
performed to explore whether or not cholesterol concentrations influenced the
concentrations of bile acids in the plasma. The mean ± SD fasting cholesterol concentration
in these patients was elevated (205 ± 102 mg/dl), but no association between cholesterol and
bile acid concentrations was noted.
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This investigation examined serum concentrations of the five major unconjugated bile acids
(CA, CDCA, DCA, LCA, UDCA) as well as one conjugated bile acid (TC). If sulfation,
glucuronidation, glycine, or taurine conjugation processes are altered, the relative
contribution of conjugated and unconjugated bile acids can change. We found no published
data on the influence of HIV infection on expression or activity of the enzymes involved in
the conjugation of bile acids, although it is known that HIV can affect drug metabolizing
enzyme activity.
Select antiretroviral agents can affect glucuronidation pathways. Ritonavir induces bilirubin
uridine 5′-diphospho– glucuronosyl-transferase (UGT), whereas indinavir and atazanavir
inhibit the activity of this enzyme.20-23 Inhibition of UGT by indinavir and atazanavir can
lead to asymptomatic elevations in unconjugated bilirubin and is not generally considered to
be true hepatotoxicity. Treatment with ritonavir-containing regimens increases the risk for
the development of hepatotoxicity.23, 24
In our investigation, the plasma concentrations of the taurine conjugate of CA (i.e., TC) in
HIV-infected patients were greater than in noninfected subjects despite normal CA
concentrations. This suggests a higher taurine conjugation of cholate in HIV-infected
patients. These findings also could be due to the inhibition of hepatic TC uptake by
antiretroviral agents. The patient who developed hepatotoxicity exhibited elevated TC
concentrations at the early time points of the dosing interval compared with the mean TC
concentrations for all study patients. It is plausible that TC uptake into the hepatocyte
through the predominant bile acid uptake transporter, sodium-dependent taurocholate
cotransporting polypeptide, was inhibited to a greater extent in this patient, resulting in
elevated plasma concentrations and predisposing this individual to the development of
hepatotoxicity.
The hepatotoxic drugs bosentan and troglitazone inhibit hepatic bile acid transport.12, 25, 26
Patients who developed hepatotoxicity while taking bosentan exhibited increased total
plasma bile acid concentrations.12 In rats, the administration of the hepatotoxic drug
nefazodone resulted in the inhibition of hepatic bile acid transport as well as a transient
increase in serum bile acid concentrations.27 In addition, in vitro data from our laboratory
have demonstrated that selected protease inhibitors inhibit bile acid transport in the liver.28
Since one patient in this clinical investigation developed hepatotoxicity, it was of interest to
measure individual bile acid concentrations to determine whether elevations might be used
as an early indicator of hepatotoxicity. The LCA is considered a toxic bile acid in several
species.29 Elevated concentrations of LCA can result in the downregulation of UGT, which
could slow the elimination of LCA and may lead to toxicity.30 In addition, HIV infection or
protease inhibitor therapy may result in an alteration in the detoxification pathways of LCA,
which could result in increased toxicities in HIV-infected patients. Of interest, in this
investigation, LCA concentrations for the patient who developed hepatotoxicity were
noticeably lower than the mean LCA concentrations for all the patients in this study. It is
conceivable that this patient may have exhibited elevated hepatic LCA concentrations but
was unable to excrete LCA into the plasma, therefore predisposing this patient to
hepatotoxicity.
It is plausible that individual protease inhibitors would have variable effects on bile acid
concentrations. In our investigations, we have demonstrated that ritonavir and saquinavir
inhibited bile acid transport in vitro and that ritonavir is a more potent inhibitor than
saquinavir.28 However, the relative effects of saquinavir and amprenavir (the drugs used in
this investigation) on bile acid transport have not yet been investigated.
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To our knowledge, this is the first investigation to describe the intra- and interindividual
variability in the concentrations of six major bile acids in a small population of HIV-infected
patients, and the first to investigate the utility of bile acid concentrations as indicators of
drug-induced liver toxicity associated with protease inhibitor therapy. The two major
limitations of this study are its small sample size and its retrospective design. The study was
not originally designed to have statistical power to detect differences in bile acid
concentrations in a hepatotoxic patient(s) versus those who did not experience
hepatotoxicity. Therefore, using inferential statistics to interpret the information presented
here has inherent limitations. However, it is rare to find robust serial pharmacokinetic
sampling in a study that contains antiretroviral-induced hepatotoxicity, and the small sample
size does not negate the potential importance of the trends found in this study.
Conclusion
Although no changes in bile acid concentrations were noted in the patient who developed
hepatotoxicity, distinctive alterations in individual bile acid concentrations and in the
relative contribution of bile acids to the bile acid pool were observed in HIV-infected
patients with advanced disease compared with non–HIV-infected control subjects. These
findings may prove to be significant for antiretroviral-induced hepatotoxicity in larger,
prospectively designed studies.
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Concentration versus time data for the six bile acids: cholic acid (CA), chenodeoxycholic
acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), taurocholic acid (TC), and
ursodeoxycholic acid (UDCA). Data are mean ± SD from the first pharmacokinetic analysis
(PK1) after dual–protease inhibitor therapy (open circles) and from PK2 after triple–protease
inhibitor therapy (closed triangles). Dotted lines (PK1) and dashed lines (PK2) represent
data from the patient who developed hepatotoxicity. Horizontal solid lines represent the
normal range of the bile acid concentration in healthy control subjects.
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Composite total bile acid exposure in all patients at pharmacokinetic visits 2 and 3. Closed
circles represent the patient who developed hepatotoxicity between PK2 and PK3.
Composite exposure was calculated as the combination of the 12-hour area under the
concentration-time curve for the six major bile acids (cholic acid, chenodeoxycholic acid,
deoxycholic acid, lithocholic acid, taurocholic acid, and ursodeoxycholic acid).
McRae et al. Page 10














Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations and
composite bile acid exposure (area under the concentration-time curve [AUC]) for the one
patient who developed drug-induced hepatotoxicity. The composite bile acid exposure was
calculated as the combination of the 12-hour AUC values for the six major bile acids (cholic
acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, taurocholic acid, and
ursodeoxycholic acid).
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Cholic acid (CA):chenodeoxycholic acid (CDCA) area under the concentration-time curve
ratios for individual patients at pharmacokinetic (PK) visits 1–3. Closed triangles represent
the patient who developed hepatotoxicity between PK2 and PK3.
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CDCA 9 37 31–50
DCA 34 18 20–37
UDCA 17 7 18
CA 5 22 13–17
TC 28 3 11
LCA 6 4 2
Data are percentages.
HIV = human immunodeficiency virus; CDCA = chenodeoxycholic acid; DCA = deoxycholic acid; UDCA = ursodeoxycholic acid; CA = cholic
acid; TC = taurocholic acid; LCA = lithocholic acid.
a
Mean result of two pooled plasma samples (consisting of contributions from three non–HIV-infected individuals each) evaluated in our assay.
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